These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1344 related articles for article (PubMed ID: 18047501)
1. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Cady R; Schreiber C Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501 [TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM; Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098 [TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD; Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567 [TBL] [Abstract][Full Text] [Related]
4. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Mathew NT; Kailasam J; Meadors L Headache; 2008 Feb; 48(2):194-200. PubMed ID: 17868356 [TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Blumenfeld AM; Schim JD; Chippendale TJ Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502 [TBL] [Abstract][Full Text] [Related]
6. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Saper JR; Mathew NT; Loder EW; DeGryse R; VanDenburgh AM; Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321 [TBL] [Abstract][Full Text] [Related]
7. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Relja M; Poole AC; Schoenen J; Pascual J; Lei X; Thompson C; Cephalalgia; 2007 Jun; 27(6):492-503. PubMed ID: 17428299 [TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of short-term preventive frovatriptan: a combined analysis. MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471 [TBL] [Abstract][Full Text] [Related]
9. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197 [TBL] [Abstract][Full Text] [Related]
10. Duration of migraine is a predictor for response to botulinum toxin type A. Eross EJ; Gladstone JP; Lewis S; Rogers R; Dodick DW Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566 [TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin type A in prophylactic treatment of migraine. Anand KS; Prasad A; Singh MM; Sharma S; Bala K Am J Ther; 2006; 13(3):183-7. PubMed ID: 16772757 [TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Silberstein SD; Göbel H; Jensen R; Elkind AH; Degryse R; Walcott JM; Turkel C Cephalalgia; 2006 Jul; 26(7):790-800. PubMed ID: 16776693 [TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial. Vo AH; Satori R; Jabbari B; Green J; Killgore WD; Labutta R; Campbell WW Aviat Space Environ Med; 2007 May; 78(5 Suppl):B113-8. PubMed ID: 17547312 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252 [TBL] [Abstract][Full Text] [Related]
16. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ; Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971 [TBL] [Abstract][Full Text] [Related]
17. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. Freitag FG; Diamond S; Diamond M; Urban G Headache; 2008 Feb; 48(2):201-9. PubMed ID: 18042229 [TBL] [Abstract][Full Text] [Related]
18. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. Sahai A; Dowson C; Khan MS; Dasgupta P BJU Int; 2009 Jun; 103(11):1509-15. PubMed ID: 19389019 [TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Naumann M; Lowe NJ; Kumar CR; Hamm H; Arch Dermatol; 2003 Jun; 139(6):731-6. PubMed ID: 12810503 [TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study. Evers S; Vollmer-Haase J; Schwaag S; Rahmann A; Husstedt IW; Frese A Cephalalgia; 2004 Oct; 24(10):838-43. PubMed ID: 15377314 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]